12 available datasets:
HLA Genotype Sequencing of Hemorrhagic Fever Survivors Systems Serology Measurements of Ebola/Lassa Patients and Survivors Systems Serology Measurements of Seattle COVID-19 Patients RT-PCR Measurements of Ebola/Lassa Patients Blood Cell Counts of Ebola/Lassa Patients Rapid Antigen Tests of Ebola/Lassa Patients Piccolo Blood Chemistry of Ebola/Lassa Patients Vital Measurements of Ebola/Lassa Patients RT-PCR Measurements of Seattle COVID-19 Patients SARS-CoV-2 Virus Sequencing Lassa Virus Sequencing Ebola Virus Sequencing

HLA Genotype Sequencing of Hemorrhagic Fever Survivors
HLAhuman leukocyte antigenEbolaEbola virusEBOVLassaLassa virusLASV

updated 15 November 2019
Human leukocyte antigen (HLA) Genotype Sequencing of EBOV/LASV survivors, non-survivors, contacts and healthy controls from Sierra Leone and Nigeria using Illumina TruSight HLA v2 Sequencing Panel. HLA data will be used to determine potential risk alleles for EBOV/LASV infection, survival and development of sequelae.
370
experiments

cohort

country

outcome

year

file type

Systems Serology Measurements of Ebola/Lassa Patients and Survivors
systems serologyEbolaEbola virusEBOVLassaLassa virusLASVserology

updated 13 February 2020
Systems Serology aims to define the features of the humoral immune response against a given pathogen. Systems Serology analysis includes measurement of the levels antigen-specific antibodies within individual patients, measurement of antibody-mediated induction of innate immune cell effector functions, measurement of binding of antigen-specific antibodies to Fc-receptors, and measurement of neutralizing activity.
2,554
experiments

cohort

country

outcome

year

file type

Systems Serology Measurements of Seattle COVID-19 Patients
Systems SerologySARS-CoV-2COVID-19Seattleserology

updated 19 October 2020
Systems Serology aims to define the features of the humoral immune response against a given pathogen. Systems Serology analysis includes measurement of the levels antigen-specific antibodies within individual patients, measurement of antibody-mediated induction of innate immune cell effector functions, measurement of binding of antigen-specific antibodies to Fc-receptors, and measurement of neutralizing activity. Samples are taken from COVID-19 patients in Seattle, Washington.
1,196
experiments

cohort

country

outcome

year

file type

RT-PCR Measurements of Ebola/Lassa Patients
RT-PCRReverse Transcriptase-Polymerase Chain ReactionPCREbolaEbola virusEBOVLassaLassa virusLASV

updated 2 November 2020
RT-PCR measurements of suspected or confirmed Ebola or Lassa Fever patients in the acute phase of infection.
778
experiments

cohort

country

outcome

year

file type

Blood Cell Counts of Ebola/Lassa Patients
blood cell countcomlete blood cell countwhole blood counthemoglobinplateletsneutrophilsbandslymphocytesmonocyteseosinophilsbasophilsprothrombin timeinternational normalization ratiodDimerEbolaEbola virusEBOVLassaLassa virusLASV

updated 2 November 2020
Blood cell count measurement data of suspected or confirmed Ebola or Lassa Fever patients in the acute phase of infection.
625
experiments

cohort

country

outcome

year

file type

Rapid Antigen Tests of Ebola/Lassa Patients
RDTRapid Diagnostic TestRapid Antigen TestMalariaPlasmodiumEbolaEbola virusEBOVLassaLassa virusLASV

updated 2 November 2020
Rapid antigen test data of suspected or confirmed Ebola or Lassa Fever patients in the acute phase of infection.
4,680
experiments

cohort

country

outcome

year

file type

Piccolo Blood Chemistry of Ebola/Lassa Patients
Piccoloblood chemsitryEbolaEbola virusEBOVLassaLassa virusLASV

updated 2 November 2020
Blood chemistry data of suspected or confirmed Ebola or Lassa Fever patients in the acute phase of infection, collected with a Piccolo Xpress Chemistry Analyzer.
1,435
experiments

cohort

country

outcome

year

file type

Vital Measurements of Ebola/Lassa Patients
vitalsbody temperaturerespiratory rateheart ratesystolic pressurediastolic pressurecoma scoreGlasgow coma scoreoxygen saturationEbolaEbola virusEBOVLassaLassa virusLASV

updated 2 November 2020
Vital measurement data of suspected or confirmed Ebola or Lassa Fever patients in the acute phase of infection, or patients and household contacts in a follow-up visit.
2,844
experiments

cohort

country

outcome

year

file type

RT-PCR Measurements of Seattle COVID-19 Patients
RT-PCRPCRSARS-CoV-2COVID-19SeattleReverse Transcriptase-Polymerase Chain Reaction

updated 19 October 2020
RT-PCR measurements of SARS-CoV-2 levels for COVID-19 patients in Seattle, Washington. Complimentary dataset to Systems Serology measurments of the same patient cohort.
11
experiments

cohort

country

outcome

year

file type

SARS-CoV-2 Virus Sequencing
SARS-CoV-2COVID-19

updated 16 November 2020
Virus sequencing of patients infected with COVID-19 from Southern California, Tijuana, New Orleans and Jordan by the SEARCH Alliance along with a large number of partners. The virus sequence data will be used to to gain insights into the emergence and spread of SARS-CoV-2. The sequencing is being performed using an amplicon-based sequencing scheme using PrimalSeq with artic nCoV-2019 scheme. Nanopore data was processed using the artic-nCoV019 pipeline with minimap2 and medaka. Illumina data was processed using iVar (Grubaguh et al. Genome Biology 2019) with bwa. Methodology is available at https://github.com/andersen-lab/HCoV-19-Genomics
2,400
experiments

cohort

country

outcome

year

file type

Lassa Virus Sequencing
virus sequencingLassaLassa virusLASV

updated 13 February 2020
Virus sequencing of Lassa-infected humans and rodents from Nigeria, Sierra Leone, Liberia, Guinea, and other countries. Virus sequence data will be used to determine potential correlations between the infecting virus genome and patient survival, disease severity and development of sequelae.
1,318
experiments

cohort

country

outcome

year

file type

Ebola Virus Sequencing
virus sequencingEbolaEbola virusEBOV

updated 16 November 2020
Virus sequencing of acute Ebola patients from Sierra Leone, Liberia, Guinea, and other countries. Virus sequence data will be used to determine potential correlations between the infecting virus genome and patient survival, disease severity and development of sequelae. When multiple sequences are available for one patient, the virus has been sequenced from that patient at several points in time.
3,024
experiments

cohort

country

outcome

year

file type